A comprehensive tissue test with an AI-powered scoring
algorithm that improves PD-L1 detection.¹*

Comprehensive results
in <2 weeks^1†

Important note: Guardant360 TissueNext and Guardant Galaxy PD-L1 were developed as Laboratory Developed Tests (LDTs), and their performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. These tests have not been cleared or approved by the US FDA.

Actionable insights with coverage of clinically relevant biomarkers¹

AI-powered precision with >20% improved PD-L1 detection^1,2*

Next >

Home Screening Monitoring: MRD Monitoring: Treatment Response Treatment Selection

AI, artificial intelligence; NSCLC, non-small cell lung cancer;
PD-L1, programmed cell death-ligand 1.
*Compared to manual pathologist interpretation in the most challenging cases in NSCLC.
†Average turnaround time from sample receipt to results.